RP
PFE icon

Raelipskie Partnership’s Pfizer PFE Stock Holding History

Raelipskie Partnership’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$876K Buy
36,369
+25,252
+227% +$661K 0.33% 54
2026
Q1 		$312K Sell
11,117
-1,347
-11% -$35.9K 0.13% 61
2025
Q4 		$310K Buy
12,464
+578
+5% +$14.6K 0.13% 60
2025
Q3 		$303K Sell
11,886
-472
-4% -$11.7K 0.13% 61
2025
Q2 		$300K Buy
12,358
+328
+3% +$7.65K 0.14% 61
2025
Q1 		$305K Sell
12,030
-2,200
-15% -$57.6K 0.16% 61
2024
Q4 		$378K Sell
14,230
-660
-4% -$17.9K 0.19% 58
2024
Q3 		$431K Sell
14,890
-825
-5% -$24.1K 0.21% 58
2024
Q2 		$440K Buy
15,715
+250
+2% +$6.88K 0.23% 57
2024
Q1 		$429K Sell
15,465
-8,128
-34% -$226K 0.24% 56
2023
Q4 		$679K Buy
+23,593
New +$713K 0.41% 49

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Raelipskie Partnership's PFE Position: Q2 2026 in Review

Raelipskie Partnership increased its Pfizer (PFE) stake by 227% in Q2 2026, buying an estimated $661K and bringing the position to 36,369 shares worth $876K. The position accounts for 0.33% of the portfolio, ranked #54.

Raelipskie Partnership first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Raelipskie Partnership held 36,369 shares of Pfizer worth $876K as of Q2 2026.
  • Raelipskie Partnership bought 25,252 Pfizer shares in Q2 2026, an estimated $661K.
  • Pfizer made up 0.33% of Raelipskie Partnership's portfolio in Q2 2026, its #54 holding.
  • Raelipskie Partnership first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
  • 2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Raelipskie Partnership's 13F filing for Q2 2026, filed 4 Aug 2026.